M. Udayabanu

In silico identification of edible mushroom-derived dual cholinesterase inhibitors as potential therapeutic candidates for Alzheimer's Disease

Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder and accounts for approximately 60–70% of dementia cases worldwide. It is characterized by progressive memory impairment, cognitive decline, and neuronal loss. Cholinergic dysfunction, resulting from elevated activities of acetylcholinesterase (...